Tangram Therapeutics is a biotechnology company using AI and RNAi to develop genetic medicines.
Tangram Therapeutics is a biotechnology company that applies artificial intelligence and RNA interference to develop genetic medicines. Its technical expertise encompasses computational drug discovery, AI, RNAi chemistry, and data integration.
The firm's key platforms include LLibra OS, an AI-powered data integration system, and GalOmic, an RNAi chemistry platform designed for potent and long-acting RNAi medicines. Its lead clinical programs are TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH) and TGM-148 for bleeding disorders.
Tangram recently achieved a clinical milestone by dosing the first participant in its Phase 1/2 RESTORE-MASH trial. Based in London, UK, the company operates within the biotechnology and pharmaceutical industries, with a focus on innovative problem-solving and cutting-edge technology.
